Launch VideoAegerion, Sanofi/Isis Face FDA Committee Review
Aegerion’s lead drug candidate lomitapide and Sanofi and partner Isis Pharmaceutical’s mipomersen will be discussed by a panel advising the FDA this week. Both drugs were developed to treat homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder.
